Live Breaking News & Updates on Editors Speak

Stay updated with breaking news from Editors speak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Wegovy™ Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity

/PRNewswire/ Results from the STEP 5 phase 3b trial, presented today at the ObesityWeek® 2021 interactive congress, showed that adults treated with Wegovy™. ....

United States , United Kingdom , World Health Organization , Obesity Society , Public Health , American Medical Association , European Medicines Agency , Novo Nordisk , Semaglutide Treatment Effect , Annual Meeting , Key Elements , Once Weekly Glucagon Like , Adopts New Policies , Second Day , Metabolism Clinics , Editors Speak , Silver Spring , Overweight Factsheet ,

Novo Nordisk receives FDA approval for Wegovy™ to treat adults with obesity based on unprecedented efficacy for a prescription medicine in clinical trials

/PRNewswire/ Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy™. ....

United States , New Jersey , Northwestern University , Doug Langa , Robert Kushner , Joe Nadglowski , Obesity Medicine Association , Obesity Action Coalition , European Union , Novo Nordisk Inc , Centers For Disease , Drug Administration , World Health Organization , World Obesity Federation , Obesity Society , American Medical Association , Feinberg School Of Medicine , Novo Nordisk , Multichannel News Release , Disease Control , Semaglutide Treatment Effect , Feinberg School , North America , Obesity Action , Important Safety Information , Multiple Endocrine Neoplasia ,

Semaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activities

Share this article
Share this article
BAGSVÆRD, Denmark, May 13, 2021 /PRNewswire/ Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to significant improvements in physical functioning, such as climbing stairs and tying your shoes, and beneficial effects on weight related and health related quality of life scores (HRQoL) compared to placebo. Following the 68-week treatment period, more than half of participants had improved quality of life scores, indicating better physical function and improved psychological wellbeing. ....

United States , Sean Wharton , Martin Holst Lange , Durrer Schutz , World Health Organization , Drug Administration , Development At Novo Nordisk , Public Health , European Medicines Agency , European Congress On Obesity , Novo Nordisk , European Congress , Wharton Medical Clinic , Semaglutide Treatment Effect , Life Lite Clinical Trials Version , Short Form , Physical Functioning , Overweight Factsheet , Weekly Semaglutide , Once Weekly , Patient Reported Outcome Measures , Health Related Quality , Adults With Overweight , Key Elements , Once Weekly Glucagon Like , Behavioral Therapy ,

Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial

Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Domenica Rubino , Durrer Schutz , Endocrine Society , Drug Administration , Washington Center , Journal Of The American Medical Association , Public Health , European Medicines Agency , Novo Nordisk , American Medical , Weight Management , Semaglutide Treatment Effect , Key Elements , Once Weekly Glucagon Like , Behavioral Therapy , Obesity Combined , Randomized Controlled , Metabolism Clinics , Editors Speak , Silver Spring , Patient Centred Guidelines , Adult Obesity Management , ஒன்றுபட்டது மாநிலங்களில் , டொமேநிக ரூபினோ , நாளமில்லா சமூகம் ,

Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial

Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Domenica Rubino , Centers For Disease , Endocrine Society , World Health Organization , Obesity Medicine Association , Washington Center , World Obesity Federation , Journal Of The American Medical Association , American Medical Association , Novo Nordisk , American Medical , Weight Management , Semaglutide Treatment Effect , Key Elements , Study Investigating How Well Semaglutide Works , People Suffering From Overweight , Last Accessed March , Once Weekly Glucagon Like , Adopts New Policies , Second Day , World Obesity , Obesity Medicine , Last Accessed , Editors Speak , Silver Spring ,